Robert W. Baird Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $42.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target trimmed by Robert W. Baird from $54.00 to $42.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages also recently issued reports on KPTI. HC Wainwright increased their price objective on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.20.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI opened at $5.44 on Tuesday. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $17.85. The company has a market cap of $46.62 million, a P/E ratio of -5.33 and a beta of 0.33. The company has a 50-day moving average of $5.41 and a 200-day moving average of $8.79.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Monday, May 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.21) by $1.44. The firm had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $35.12 million. As a group, equities research analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several large investors have recently added to or reduced their stakes in KPTI. Velan Capital Investment Management LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $27,000. Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $31,000. TD Waterhouse Canada Inc. acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $32,000. Two Sigma Advisers LP increased its holdings in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares during the period. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $85,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).